OUR RECENT PUBLICATIONS

Our research spans a broad range of topics relevant to the biopharma industry, and has led to several peer-reviewed articles. For more information about our research activities or reprints of paywalled papers, contact us at info@pharmagellan.com.

 
fig1a-tot.png

historical trends in pharma R&D spending

Prior analyses of pharma R&D and SG&A spending have focused on each category as a percent of revenues. In this work, we instead look at historical trends over time to discover how drug companies choose to allocate resources, particularly when revenues are pressured.

 

POTENTIAL CLINICAL IMPACT OF "RECIPROCAL APPROVAL" LEGISLATION

Pharma regulatory strategy would be radically transformed if the FDA were compelled to automatically consider drugs already approved in other countries for market approval. In this cohort analysis, we measure how U.S. patients could be affected by this proposed policy.

 
fig - launch curve.png

Drug launch curves in the modern era

The historical view of prototypical drug launches is based on 30-year-old work focused on cardiovascular medicines. Here, we update those data and provide a revised view of ramp rates of "pioneer" and "follower" drugs.

 
fig - fin adap trials.jpg

CREATING VALUE WITH FINANCIALLY ADAPTIVE CLINICAL TRIALS

Clinical development planning and financial analysis are traditionally conducted in separate silos. In this piece, we illustrate the benefits that drug companies can reap by integrating these activities.